Targeted il-12 therapy and methods for stimulating HANK and NK92mi cells
Through contact with chimeric proteins by IL-2-sensitized NK cells, IFNγ secretion is induced, which solves the problems of reduced cytotoxic activity and high systemic toxicity of NK92 cells in the prior art, and achieves targeted therapeutic effects in cancer sites.
Patent Information
- Application Number
- CN202411089884.2
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Priority Date
- 2018-09-07
- Filing Date
- 2019-09-05
- Publication Date
- 2024-11-19
AI Technical Summary
Existing cell-based cancer treatment methods, especially the use of NK92 cells, have problems with reduced cytotoxic activity and high systemic toxicity, making it difficult to stimulate NK cells safely and effectively with IL-12 in clinical practice.
To induce interferon gamma secretion of NK cells (IFNγ) by providing IL-2-sensitized NK cells and contacting them with chimeric proteins containing IL-12 moieties and cancer cell-targeting moieties to induce NK cells to secrete interferon gamma (IFNγ) to improve cytotoxicity and reduce cytotoxicity Systemic toxicity.
It is achieved to significantly increase the secretion and cytotoxicity of IFNγ in cells, avoid systemic toxicity, and the secretion of IFNγ is specific to the cancer site, enhancing the immune response in the tumor.
Smart Images

Figure CN118976120A_ABST
Abstract
Description
[0001] This application is a divisional application of an invention patent with an application date of September 5, 2019, application number 201980058286.X, and invention name “Targeted IL-12 therapy and method for stimulating HANK and NK92MI cells”.
[0002] This application claims priority to our U.S. Provisional Patent Application Serial No. 62 / 728,510, filed on September 7, 2018, which is incorporated herein by reference. Technical Field
[0003] The field of the invention is cancer treatment and methods using natural killer cells and immunostimulatory cytokines, and in particular activated NK cells and IL-12. Background Art
[0004] The Background Description includes information that may be useful in understanding the present invention. It is not an admission that any of the information provided herein is prior art or relevant to the presently claimed invention, nor is it an admission that any publication explicitly or implicitly referenced is prior art.
[0005] All publications and patent applications are incorporated herein by reference to the same extent as if each individual publication or patent application was specifically and individually indicated to be incorporated by reference. Where a definition or use of a term in an incorporated reference is inconsistent or contrary to the definition of that term provided herein, the definition of that term provided herein applies and the definition of that term in the reference does not apply.
[0006] Recently, due to positive treatment results, cell-based cancer treatment with genetically modified NK cells has received attention, especially using NK92-derived cells, such as activated NK cells (aNK cells), genetically modified NK cells with high-affinity CD16 receptors (haNK cells), or chimeric antigen receptors (taNK cells). Although such cell-based therapies are conceptually attractive, the tumor microenvironment and other patient-specific factors will generally reduce their cytotoxic activity, and various attempts have been made to modulate cytotoxicity in NK92 cells.
[0007] Interleukin-2 (IL-2) and interleukin-12 (IL-12) cytokines induce strong anti-tumor effects by stimulating unmodified immune cells (including T cells and natural killer (NK) cells). Although cytokines stimulate T cell proliferation, interferon-γ (IFN-γ) production of NK cells, and ultimately by IL-2 and IL-12 stimulation of cytolytic activity, amplitude and spectrum are all different (see, e.g., J.Leukoc.Biol. [Journal of White Cell Biology] 58: 225-233; 1995). For example, although IL-2 is a stronger stimulator of proliferation and cytolytic activity, IL-12 is a stronger inducer of IFN-γ from unmodified NK cells and activated T cells. IFN-γmRNA has increased stability in NK cells co-stimulated with IL-2 and IL-12 (see, e.g., Molecular and CellularBiology [Molecular and CellularBiology], March 2002, pp. 1742-53). However, the IL-2 and IL-12 concentrations used in vitro may not necessarily reflect the levels that are achievable or even desirable in vivo. In fact, systemic administration of IL-2 is associated with relatively high toxicity and capillary leak syndrome, while several deaths have been attributed to systemic administration of IL-12. In addition, the response of primary NK cells to various cytokines is not necessarily the same as that of genetically modified NK92 cells.
[0008] Thus, while various compositions and methods for activating NK cells are known, there remains a need for compositions and methods for using NK cells to treat cancer, particularly where NK cells are stimulated with IL-12 in a clinically safe manner. Summary of the invention
[0009] Various compositions and methods for NK cell-based treatments are disclosed herein. In particular, the disclosure describes NK cells that express and retain IL-2 intracellularly, wherein the NK cells are stimulated using a chimeric protein comprising a cancer cell targeting portion and an IL-12 portion. Advantageously, this chimeric protein substantially reduces systemic toxicity and beneficially induces IFN-γ secretion in a targeted manner. Unexpectedly, compared to natural NK cells, this chimeric protein significantly increases the secretion of IFN-γ in NK cells that express and retain IL-2 intracellularly.
[0010] In one aspect of the inventive subject matter, the inventors contemplate a method for inducing IFNγ secretion in NK cells, the method comprising a step of providing NK cells, wherein the NK cells are IL-2-sensitized NK cells or genetically modified NK cells that constitutively express IL-2; and another step of contacting the NK cells with a chimeric protein comprising an IL-12 portion and a cancer cell targeting portion to induce the NK cells to secrete interferon gamma (IFNγ).
[0011] In some embodiments, the IL-2 sensitized NK cells are NK cells previously and constitutively exposed to IL-2 or NK cells constitutively exposed to at least 100 IU / mL IL-2. In other embodiments, the genetically modified NK cells may also be aNK cells, autologous NK cells, or NK cells derived in vitro from precursor cells, and in still other embodiments, the genetically modified NK cells constitutively express and retain IL-2 (e.g., haNK cells or NK92MI cells) in the cells.
[0012] It is further contemplated that the IL-12 portion of the chimeric protein comprises an IL-12 alpha chain and an IL-12 beta chain, but homodimers and other heterodimers of the IL-12 alpha chain are also considered suitable. In some embodiments, the cancer cell targeting portion comprises an IgG antibody portion, a Fab portion, a F(ab')2 portion, a Fab2 portion, or a scFv portion. Most typically, the cancer cell targeting portion targets a necrosis marker (e.g., DNA, RNA, histone, etc.) or a cancer-associated antigen or cancer neo-epitope to provide site specificity for IL-12 action. For example, a suitable cancer cell targeting portion may comprise the hu51-4 antibody or a portion thereof.
[0013] Although not limited to the present subject matter, it is contemplated that the step of contacting the NK cell with the chimeric protein is performed ex vivo, and the NK cell is a haNK cell, or that the step of contacting the NK cell with the chimeric protein is performed in vivo, and wherein the NK cell is a haNK cell or a NK92MI cell.
[0014] Therefore, from a different perspective, the inventors also anticipate a method for treating cancer, which comprises the step of administering to a patient NK cells, wherein the NK cells are IL-2-sensitized NK cells or genetically modified NK cells that constitutively express IL-2; and an additional step of administering a chimeric protein comprising an IL-12 portion and a cancer cell targeting portion to induce the NK cells to secrete interferon γ (IFNγ).
[0015] As described above, it is contemplated that the NK cell may be a genetically modified NK cell (e.g., a haNK cell or a NK92MI cell) that constitutively expresses and retains IL-2 intracellularly, and / or the IL-12 portion of the chimeric protein comprises an IL-12 α chain and an IL-12 β chain. In other examples, the cancer cell targeting portion may comprise an IgG antibody portion, a Fab portion, a F(ab')2 portion, a Fab2 portion, or a scFv portion, and it is generally preferred that the cancer cell targeting portion targets a necrosis marker (e.g., DNA, RNA, histone, etc.) or a cancer-associated antigen or cancer neo-epitope. For example, the cancer cell targeting portion may comprise a hu51-4 antibody or a portion thereof.
[0016] In other embodiments, it is contemplated that the chimeric protein is administered at least 12 hours before the NK cells are administered, or at least 12 hours after the NK cells are administered, or the chimeric protein is administered simultaneously with the NK cells. In other selections, it is also contemplated that the chimeric protein is combined with NK cells.
[0017] In yet another aspect of the inventive subject matter, the inventors also contemplate a chimeric protein comprising an IL-12 portion and a cancer cell targeting portion that targets a necrosis marker (e.g., DNA, RNA, histone, etc.), and / or the cancer cell targeting portion comprises a hu51-4 antibody or a portion thereof. In other embodiments, the cancer cell targeting portion comprises an IgG antibody portion, a Fab portion, a F(ab')2 portion, a Fab2 portion, or a scFv portion.
[0018] For example, the IL-12 portion can be covalently coupled to the cancer cell targeting portion, and / or the IL-12 portion can be covalently coupled to the cancer cell targeting portion via a peptide linker. Typically, but not necessarily, the IL-12 portion of the chimeric protein comprises an IL-12 alpha chain and an IL-12 beta chain, and / or the cancer cell targeting portion comprises a hu51-4 antibody or a portion thereof. When desired, the chimeric protein can non-covalently bind to the CD16 receptor of NK cells.
[0019] Therefore, the inventors also contemplate pharmaceutical compositions comprising chimeric proteins contemplated herein. Such pharmaceutical compositions may further comprise NK cells as described above. Therefore, the inventors also contemplate a kit comprising: (a) NK cells, wherein the NK cells are IL-2-sensitized NK cells or genetically modified NK cells constitutively expressing IL-2; and (b) a chimeric protein comprising an IL-12 portion and a cancer cell targeting portion. With regard to NK cells and chimeric proteins, the same considerations as provided above apply.
[0020] Therefore, from a different perspective, the inventors also contemplate the use of chimeric proteins and NK cells in the treatment of cancer, wherein the NK cells are IL-2 sensitized NK cells or genetically modified NK cells constitutively expressing IL-2, and wherein the chimeric protein comprises an IL-12 portion and a cancer cell targeting portion, inducing the NK cells to secrete interferon gamma (IFNγ). With respect to NK cells and / or chimeric proteins, the same considerations as above apply.
[0021] Various objects, features, aspects and advantages of the inventive subject matter will become more apparent from the following detailed description of preferred embodiments and the accompanying drawings, in which like reference numerals represent like components. BRIEF DESCRIPTION OF THE DRAWINGS
[0022] Figure 1 Exemplary graphs are shown demonstrating that the NK cells tested require constitutive IL-2 expression / exposure to achieve significant IL-12-mediated IFN-γ secretion.
[0023] Figure 2 is an exemplary graph showing the biological activity of IL-12 and selected chimeric proteins comprising an IL-12 portion relative to IL-12-mediated IFN-γ secretion.
[0024] Figure 3 is an exemplary graph showing the binding of a selected chimeric protein comprising an IL-12 portion linked to an antigen exposed to cell death.
[0025] Figure 4 The sequences of exemplary chimeric proteins comprising an IL-12 portion are shown. DETAILED DESCRIPTION
[0026] The inventors have now discovered that selected chimeric molecules comprising an IL-12 portion can be used in an effective and targeted manner to induce IFNγ secretion in IL-2-sensitized NK cells or in genetically modified NK cells constitutively expressing IL-2, thereby enhancing cytotoxic NK cell activity in target tissues. Advantageously, chimeric molecules comprising an IL-12 portion help to avoid the toxicity otherwise produced when IL-12 is administered systemically. In addition, since the chimeric molecule also comprises a cancer targeting portion (e.g., targeting one or more necrosis markers), inducing NK cells to secrete IFNγ can be specific to the cancer site, and is particularly specific to hypoxia and / or necrotic tumor cores. Therefore, due to targeting specific IFNγ secretion, the expected compositions and methods will increase the presentation of antigens in tumors and the MHC-I / II expression of immune competent cells (and especially CD4+ and / or CD8+T cells), and bias the immune response in tumors toward a Th1 response.
[0027] Advantageously, the use of chimeric molecules described herein not only avoids the toxicity that would otherwise be produced when IL-12 is administered systemically, but also provides concentrated, therapeutically effective amounts of IL-12 at targeted tumor sites. In addition, it will be appreciated that the use of necrosis markers in the context of this invention will advantageously allow tumor antigen-independent antigens to spread in the tumor microenvironment, since the chimeric molecules will indiscriminately target necrotic tissues rather than cancer or tumor-associated antigens. In a further advantageous aspect, the chimeric molecules herein retain the biological activity of IL-12 heterodimers (as discussed in more detail below).
[0028] In addition, it should be particularly recognized that various NK cells cannot respond to IL-12, even when using IL-2 provided in the culture medium for breeding. However, it is worth noting that the inventors also found that when IL-2 is provided to the same cells in a constitutive or continuous manner, these cells are sensitive to IL-12 signaling. The NK cells treated in this way produce a significant amount of IFNγ and have increased cytotoxicity, presumably due to increased intracellular concentration and / or reduced fluctuations in IL-2 amounts.
[0029] The term 'constitutive exposure' or 'constitutively exposed' in conjunction with IL-2 as used herein means that biologically active IL-2 is provided or produced in a continuous (or semi-continuous) manner, such that the change in the concentration of biologically active IL-2 at or within the cell (or IL-2 stimulation) will not vary by more than 20% in 48 hours. Thus, in some embodiments, the change in the concentration of biologically active IL-2 at or within the cell (or IL-2 stimulation) will not vary by more than 15% in 48 hours, or by more than 10% in 48 hours, or by more than 7% in 48 hours, or by more than 5% in 48 hours, or by more than 1% in 48 hours. Similarly, the term "constitutive expression" or "constitutively expressed" in conjunction with IL-2 as used herein means that IL-2 is expressed in a continuous manner (recombinantly) in the cell from a constitutive promoter (i.e., no induction is required). Most typically, such expression of IL-2 in the cell is achieved by using an endoplasmic reticulum retention sequence fused to IL-2 to reduce or even completely avoid secretion in cells expressing such modified IL-2.
[0030] While not limited to the present subject matter and not being bound by theory, it is hypothesized that constitutive exposure to IL-2 in a natural setting is more similar to the exposure of NK cells to IL-2, resulting in a persistent sensitivity to IL-12 and IFNγ secretion triggered by exposure to IL-12. In contrast, intermittent exposure of NK-92 cells to IL-2—as is the case in conventional NK-92 cell cultures, where the culture medium is refreshed every two to three days—can result in inactivation and / or degradation of biologically active IL-2, perhaps due to binding to serum proteins or proteolysis by serum proteases of the culture medium. Therefore, and without wishing to be bound by any theory or hypothesis, the inventors believe that conventional NK-92 cell culture conditions promote intermittent or "pulsatile" IL-2 signaling, which supports the growth of NK-92 cells but does not support cell signaling that renders NK-92 cells sensitive to IL-12 and IL-12-dependent secretion of IFNγ and increased NKG2D expression (as compared to non-IL-12 stimulated cells).
[0031] With regard to the intended chimeric protein, it is generally believed that all chimeric proteins comprising at least one biologically active IL-12 portion are suitable. In addition, it is generally preferred that the chimeric protein also includes a portion that prolongs serum half-life, reduces systemic toxicity, and / or allows targeted delivery and / or accumulation of a specific IL-12 at a desired site. Therefore, with regard to the non-IL-12 portion of the chimeric protein, suitable non-IL-12 portions include various serum proteins and portions thereof, and in particular albumin, lactoferrin, and various globulins. Therefore, a preferred non-IL-12 portion comprises an antibody or a fragment thereof. It is easy to understand that the use of an antibody or a fragment thereof will beneficially allow targeting while also prolonging the stability and persistence of the chimeric protein in the blood. For example, the non-IL-12 portion can be an antibody heavy chain, an antibody light chain (or a portion thereof), or an scFv.
[0032] Although any binding specificity of such an antibody or fragment thereof is generally considered suitable, particularly preferred antibodies will bind specifically to an antigen of a tumor cell. For example, a suitable antibody may bind to a tumor-associated antigen, a tumor-specific antigen, or a patient- and tumor-specific neoantigen (neo-epitope). Therefore, the non-IL-12 portion is most preferably also used to deliver and retain IL-12 at the tumor site to concentrate the biological effect of IL-12 on the target site. In addition, it should be recognized that all sources of antibodies are considered suitable, including human antibodies and all isotypes, non-human mammalian forms, humanized forms, and synthetic antibodies. When the non-IL-12 portion is not an antibody, tumor selectivity or preference can nevertheless be achieved by albumin, which is preferentially taken up into tumor cells from new blood vessels by gp60-mediated transcytosis.
[0033] With respect to the IL-12 portion, it should be noted that IL-12 is a heterodimer and that the IL-12 portion of the chimeric protein can be a single chain form of IL-12 (i.e., scIL-12) or a single subunit (i.e., IL-12α subunit (p35) and IL-12β subunit (p40)) or an active portion thereof. With respect to the source of IL-12, it is generally preferred that the source is human IL-12. However, various other non-human (preferably mammalian) IL-12 forms are also expressly contemplated herein. In addition, it should be understood that splice variants and mutants are also suitable, as long as such forms exhibit at least some biological activity (e.g., inducing IFNγ secretion in haNK cells as described herein).
[0034] Suitable IL-12 protein sequences include human sequences that can form disulfide-linked heterodimers formed from IL-12α subunits (p35) and IL-12β subunits (p40) or can be covalently linked together by flexible peptide linkers (described in more detail below). Among other suitable sequences, IL-12 sequences include publicly available protein sequences (e.g., P29460 and P29459 of UniProt), as well as all natural and synthetic variants thereof, including truncated forms, splice variants, and mutant forms. Similarly, DNA and RNA sequences encoding IL-12 are known in the art, and suitable sequences include those in gene banks (accession number AC010370 for genomic sequences of IL-12α subunits and M65271 for mRNA; accession number AF512686 for genomic sequences of IL-12β subunits and M65290 for mRNA). In addition, it should be understood that other non-human sequences, preferably mammalian sequences, are also considered to be suitable for use herein.
[0035] Heterodimers of IL-12α subunit and IL-12β subunit can be formed by non-covalent association, or by a flexible peptide linker such as a G4S linker, to form a single-chain IL-12 molecule. In addition, the chimeric protein may also include an addressing sequence or leader sequence, a linker, a tag, and / or a marker (for quantification and / or simplified purification). The correct choice depends at least in part on the specific choice of production system, which is well known in the art.
[0036] It is further contemplated that the production of chimeric proteins having an IL-12 portion and a non-IL-12 portion may vary greatly and include covalent coupling of the two heavy chains as well as non-covalent coupling. For example, as described in more detail below, the necrosis-targeted antibody hu51-4 is used as a fusion partner for single-chain IL-12 (scIL-12). Similarly, NHS-IL12 is a chimeric construct comprising two molecules of IL-12 fused to a tumor necrosis-targeted human IgG1 (NHS76). The addition of the human IgG1 portion results in a longer plasma half-life for NHS-IL12 than recombinant IL-12 and the ability to selectively target murine tumors in vivo. Data from both in vitro assays using human PBMCs and in vivo primate studies showed that IFNγ production by immune cells was attenuated after treatment with immunocytokines, indicating that the toxicity profile was improved compared to the use of recombinant IL-12 alone. NHS-IL12 was also superior to recombinant IL-12 when evaluated as an antitumor agent in three murine tumor models (see, e.g., Oncotarget 2014 Apr 15;5(7):1869-84).
[0037] As will be readily appreciated, such antibody-cytokine conjugates can be prepared by chemical conjugation using a cleavable (e.g., via a disulfide bond or hydrolysis zone (hydrozone) or proteolytic site, etc.) or non-cleavable linker (e.g., via maleimide-modified PEG). Alternatively, as shown in more detail below, the conjugate can also be made using recombinant cloning, in which the N-terminus or C-terminus of the heavy or light chain (or fragment thereof) is modified to also encode the linker portion and IL-12 in frame. Thus, a chimeric recombinant protein can be prepared having an antibody portion, a linker, and an IL-12 portion that preferentially binds to a component of a tumor cell. Notably, as shown in more detail below, an exemplary antibody-drug conjugate with IL-12 retains significant activity.
[0038] Thus, an exemplary fusion protein may comprise a chimeric protein having a leader peptide portion, a mouse scIL-12 portion in normal type font (G4S linker in bold), and a hu51-4 antibody heavy chain portion (as shown in SEQ ID NO: 1), wherein the italic sequence represents the leader peptide portion and the underlined sequence represents the hu51-4 antibody heavy chain portion.
[0039]
[0040] Another exemplary fusion protein can comprise a chimeric protein of a leader peptide portion, a human scIL-12 portion in normal type font (G4S linker in bold), and a hu51-4 antibody heavy chain portion (as shown in SEQ ID NO: 2), wherein the italic sequence represents the leader peptide portion and the underlined sequence represents the hu51-4 antibody heavy chain portion.
[0041]
[0042] Still another exemplary protein comprises a leader peptide portion and a hu51-4 antibody light chain portion (as shown in SEQ ID NO: 3), wherein the italic sequence represents the leader peptide portion and the underlined sequence represents the hu51-4 antibody light chain portion.
[0043]
[0044] Regarding NK cells, it is generally expected that preferred NK cells are IL-2-sensitized NK cells or genetically modified NK cells that constitutively express IL-2. In this context, it should be noted that IL-2-sensitized cells are cells that have been treated with constitutive exposure to IL-2 as described above.
[0045] Although constitutive exposure can be accomplished by continuous exposure and / or supplementing the culture medium with IL-2 as described herein, it is more preferred that the constitutive exposure of NK / NK92 cells and their derivatives to IL-2 is achieved by intracellular expression of recombinant IL-2 in each cell. Typically, intracellular expression is driven by a constitutively active promoter to achieve a constant expression level, and is expressed in a non-secreted form (i.e., lacking an output signal sequence, and may include an endoplasmic reticulum or cytoplasmic retention sequence). It is believed that this intracellular expression provides the same functional effects on cells as the constitutive exposure of externally provided IL-2. In fact, as shown in more detail below, the inventors found that when NK92 cells or derivative cells are genetically engineered to express and retain IL-2 in the cell, the cells are unexpectedly sensitized by IL-12 stimulation, as measured by IFNγ secretion and / or increased expression of NKG2D. As will be readily appreciated, recombinant expression and intracellular retention of IL-2 can be performed in a variety of ways, and all such methods are considered applicable herein (see, e.g., Oncotarget 2016 Dec 27; 7(52): 86359-86373 or Exp Hematol. 2005 Feb; 33(2): 159-64). Among other benefits, it should be noted that such recombinant cells can be administered to a patient in vivo without the need to administer IL-2 to the same patient. Such modified cells will be sensitized to IL-12 to secrete IFNγ upon IL-12 stimulation. Indeed, sensitization to constitutive exposure (external or internal) of IL-2 provides a large amount of IFNγ, which is believed to provide a therapeutic effect in the context of concomitant immunotherapy, particularly because NKG2D expression is also significantly increased in such stimulated cells.
[0046] For example, genetically engineered NK cells can be NK-92 derivatives modified to express high-affinity Fcγ receptors (CD16). The sequences of high-affinity variants of Fcγ receptors are well known in the art (see, e.g., Blood [blood] 2009113: 3716-3725), and all production and expression methods are considered to be applicable to this article. It is believed that the expression of such receptors allows the use of antibodies specific to the patient's tumor cells (e.g., new epitopes), specific tumor types (e.g., her2neu, PSA, PSMA, etc.), or antibodies associated with cancer (e.g., CEA-CAM) to specifically target tumor cells. Advantageously, such antibodies are commercially available and can be used in conjunction with cells (e.g., bound to Fcγ receptors), and such modified cells can also be commercially available from NantKwest as haNK cells (high-affinity natural killer cells). Alternatively, NK92MI cells (see, e.g., Hum Gene Ther. 1999 May 20; 10(8): 1359-73 or US 8034332) have been reported to express and retain IL-2 intracellularly and are commercially available from ATCC.
[0047] As described above, in further contemplated aspects, regarding NK cells, it is contemplated that NK cells are considered suitable for use herein, as long as such cells are constitutively exposed to IL-2 and express (and retain) IL-2 intracellularly. Therefore, suitable alternative NK cells include autologous NK cells from patients (e.g., separated from whole blood, or cultured from precursors or stem cells using methods known in the art) and respective allogeneic NK cells. However, in preferred aspects of the subject matter of the present invention, NK cells are genetically engineered to obtain one or more desired traits, and particularly include NK-92 cells and derivatives thereof. For example, suitable genetically engineered NK cells include NK-92 derivatives modified to reduce or eliminate the expression of at least one killer cell immunoglobulin-like receptor (KIR), and KIR causes such cells to be constitutively activated (via lack or reduced inhibition).
[0048] Therefore, suitable NK cells can have one or more modified KIRs, which are mutated to reduce or eliminate the interaction with MHC class I molecules. Of course, it should be noted that one or more KIRs can also be deleted or their expression can be inhibited (e.g., by miRNA, siRNA, etc.). Most typically, more than one KIR will be mutated, deleted or silenced, and the KIRs particularly expected include those with two or three domains, with short or long cytoplasmic tails. From different perspectives, modified, silent or missing KIRs will include KIR2DL1, KIR2DL2, KIR2DL3, KIR2DL4, KIR2DL5A, KIR2DL5B, KIR2DS1, KIR2DS2, KIR2DS3, KIR2DS4, KIR2DS5, KIR3DL1, KIR3DL2, KIR3DL3, and / or KIR3DS1. Such modified cells can be prepared using protocols well known in the art. Alternatively, such cells may also be obtained commercially as aNK cells ('activated natural killer cells') from NantKwest (see URL www.nantkwest.com).
[0049] NK-92 cells show unusual receptor expression spectrum, expressing relatively large amounts of activated receptors (e.g., NKp30, NKp46, 2B4, NKGD, CD28). On the contrary, NK-92 cells also express few inhibitory receptors (e.g., NKGA / B, low levels of KIR2DL4, ILT-2), and lack most of the killer inhibitory receptors (KIR) cloned and expressed on normal NK cells. In addition, NK-92 expresses relatively high levels of molecules involved in the perforin-granzyme cytolysis pathway and other cytotoxic effector molecules (including tumor necrosis factor (TNF)-superfamily member FasL, TRAIL, TWEAK, TNF-α), indicating the ability of killing via alternative mechanisms. Moreover, NK-92 cells also express other molecules (CD80, CD86, CD40L, TRANCE) regulated by immune effector cells, and the correlation of these molecules in NK killing is unclear.
[0050] Therefore, the inventors expect that NK-92 cells and derivatives thereof can be sensitized by IL-12 and exhibit an IL-12-dependent IFNγ secretion phenotype by constitutively exposing the cells to IL-2. For example, in one embodiment, constitutive exposure can be performed by continuously or semi-continuously adding IL-2 to the culture medium, thereby keeping the concentration of biologically active IL-2 substantially constant. Therefore, it is expected that the concentration of biologically active IL-2 in the culture medium will not change by more than 15%, or by no more than 10%, or by no more than 7%, or by no more than 5%, or by no more than 3% within 48 hours. The biological activity of IL-2 can be quantified using known methods, such as using a CTLL-2 cell proliferation assay (J Immunol Methods. [Journal of Immunology] August 31, 2009; 348 (1-2): 83-94).
[0051] Continuous or semi-continuous addition of IL-2 can be carried out in a variety of ways (including using a peristaltic pump or a metering syringe). Alternatively, and in less preferred aspects, continuous or semi-continuous addition of IL-2 can be carried out by updating the medium in a frequent manner (e.g., every two hours, every four hours, every eight hours, etc.). When multiple or continuous additions are non-preferred, the inventors also expect that compositional exposure can also be achieved using a formulation that releases IL-2 in a relatively slow manner. For example, the delayed release of IL-2 (or increased stability for anti-protein binding and / or protease digestion) can be accomplished by the PEGylation of IL-2 as known from NKTR-214 (Nektar Therapeutics; 455 Mission Bay Avenue South; San Francisco, California, CA94158). Here, it is believed that PEGylated IL-2 is a prodrug form of biologically active IL-2, which releases the PEG chain over time to produce biologically active IL-2 (PLoS One [Public Library of Science Journal]. 2017 July 5; 12 (7): e0179431). Advantageously, such PEGylated IL-2 can be administered systemically, and thus allows constitutive exposure of NK / NK92 cells and their derivatives to IL-2 in vivo, while at the same time reducing the systemic side effects of IL-2, or even completely avoiding them. Advantageously, continuous exposure is performed for at least 6 hours, or at least 12 hours, or at least 24 hours, or at least 36 hours, or at least 48 hours.
[0052] Alternatively, or in addition, it should be noted that constitutive exposure can also be achieved using antibody-conjugated IL-2, as such conjugates have shown increased stability, which may be due to reduced binding to serum proteins and reduced proteolysis by serum proteases. Once again, such antibody-drug conjugates will be advantageously administered to patients in vivo. However, in this embodiment (and in contrast to NKTR-214), it is possible to deliver IL-2 and activate NK cells with high specificity and selectivity with respect to the location under consideration. For example, such antibody-drug conjugates can target tumor markers that are patient- and tumor-specific (i.e., tumor new epitopes), cancer-associated, cancer-specific, or specific to necrotic tissue common in the tumor microenvironment. Of course, it should be understood that the antibody portion in such antibody-drug conjugates can be a complete IgG antibody, or any suitable fragment thereof (e.g., scFv, Fab, Fab', F(ab')2, etc.).
[0053] Regardless of the specific form of IL-2, it is generally expected that the constitutive exposure of NK / NK92 cells and their derivatives to IL-2 (and modified forms of IL-2) will be between about 10-50 IU / mL, or between about 50-150 IU / mL, or between about 150-300 IU / mL, or between about 300-500 IU / mL, or between about 500-1000 IU / mL, or even higher (as determined by a CTLL-2 amplification assay) concentration. Moreover, it is generally expected that the IL-2 concentration remains substantially constant over at least a limited period of time. For example, it is generally preferred that the concentration fluctuation of biologically active IL-2 is less than 25%, or less than 20%, or less than 15%, or less than 10%, or less than 7%, or less than 5%, or less than 3%, as measured in a 72 hour period, or in a 60 hour period, or in a 48 hour period, or in a 36 hour period, or in a 24 hour period, or in a 18 hour period. Thus, from a different perspective, the suitable concentration of biologically active IL-2 will be maintained between 50-70 IU / mL, or between 70-100 IU / mL, or between 100-120 IU / mL, or between 120-150 IU / mL, or between 150-200 IU / mL, or between 200-230 IU / mL, or between 230-250 IU / mL, or between 250-280 IU / mL, or higher throughout the cell culture.
[0054] In another aspect of the subject matter of the present invention, genetically engineered NK cells can also be genetically engineered to express chimeric T cell receptors. In particularly preferred aspects, chimeric T cell receptors will have scFv moieties or other extracellular domains with binding specificity for tumor-associated antigens, tumor-specific antigens, and cancer neo-epitopes. As previously mentioned, there are many ways for genetically engineered NK cells to express this chimeric T cell receptor, and it is believed that all methods are applicable to this article. Alternatively, such cells can also be commercially available from NantKwest as taNK cells ('target-activated natural killer cells').
[0055] In the case where cells are engineered to have affinity for cancer-associated antigens or antibodies specific for cancer-associated antigens (e.g., via CAR expression), it is expected that all known cancer-associated antigens are considered suitable for use. For example, cancer-associated antigens include CEA, MUC-1, CYPB1, etc. Similarly, in the case where cells are engineered to have affinity for cancer-specific antigens or antibodies specific for cancer-specific antigens, it is expected that all known cancer-specific antigens are considered suitable for use. For example, cancer-specific antigens include PSA, Her-2, PSA, brachyury, etc. In the case where cells are engineered to have affinity for cancer neo-epitopes or antibodies specific for cancer neo-epitopes, it is expected that all known ways of identifying neo-epitopes will produce suitable targets. For example, whole genome analysis of tumor biopsy (or lymph biopsy or biopsy of metastatic sites) and matched normal tissue (i.e., non-diseased tissue from the same patient) can be performed, and the omics information obtained by synchronous comparison is used to identify neo-epitopes from patient tumors in the first step. The identified new epitopes can then be further filtered for matching the patient's HLA type to increase the likelihood of new epitope antigen presentation. Most preferably, this matching can be accomplished via computer simulation. In addition, all NK cells contemplated herein can also be genetically modified to express non-secreted IL-2 (e.g., retained in the ER compartment).
[0056] Thus, in yet another aspect of the inventive subject matter, the NK cells thus stimulated can be used in a pharmaceutical composition or kit (as described herein), typically formulated to have 10 4 -10 11 cells, and more typically 10 5 -10 9Aseptic injectable composition of individual cells / dosage unit. When necessary, these cells can be irradiated at a suitable radiation dose to prevent further proliferation after administration. However, alternative formulations are also considered to be applicable herein, and all known routes and modes of administration are contemplated herein. As used herein, the term "administering" a pharmaceutical composition or drug refers to direct and indirect administration of a pharmaceutical composition or drug, wherein direct administration of a pharmaceutical composition or drug is typically performed by a health care professional (e.g., a physician, a nurse, etc.), and wherein indirect administration includes providing a pharmaceutical composition or drug to a health care professional or making a pharmaceutical composition or drug available to a health care professional for direct administration (e.g., via injection into a tumor, infusion, oral delivery, local delivery, etc.). Additionally, or alternatively, as described herein, it is contemplated that pharmaceutical compositions and kits may include a chimeric protein comprising an IL-12 portion and a cancer cell targeting portion.
[0057] Therefore, the inventors particularly contemplate a method for treating cancer, wherein the constitutively stimulated natural killer cells and chimeric proteins contemplated herein are co-administered. As will be readily understood, this administration can follow various protocols. For example, when NK cells comprise high-affinity CD16 receptors (e.g., haNK cells), chimeric proteins can be coupled to NK cells by the receptor. On the other hand, for example, when NK cells are autologous NK cells, the NK cells can be stimulated by constitutively being exposed to IL-2 as described herein, and then subsequently administered to the patient separately (together) from the chimeric protein. Therefore, the chimeric protein can be administered first, and then the stimulated NK cells are administered 12-24 hours or longer. On the other hand, when the patient has been infused with NK cells (e.g., haNK cells, NK92MI cells) constitutively expressing IL-2, the chimeric protein can be administered after being treated with NK cells.
[0058] Furthermore, as expected, the method is also believed to increase NKD2D surface expression on various cells in addition to IFNγ secretion, and in particular immune competent cells (such as NK cells, CD8 + and CD4 + T cells), it is further contemplated that the treatment may also include one or more steps to enhance or trigger the expression and presentation of NKG2D ligands. For example, such steps include low-dose chemotherapy and / or low-dose radiotherapy, typically at a dose equal to or less than 50%, equal to or less than 30%, equal to or less than 20%, or equal to or less than 10% of the maximum tolerated dose. Moreover, such low-dose treatment will preferably be performed in a rhythmic manner, for example, alternating days, or every three days, or once a week for several weeks, etc.
[0059] Other embodiments
[0060] Example 1. A method for inducing IFNγ secretion in NK cells, the method comprising: contacting the NK cells with a chimeric protein comprising an IL-12 portion and a cancer cell targeting portion to induce the NK cells to secrete interferon γ (IFNγ), wherein the NK cells are IL-2-sensitized NK cells or genetically modified NK cells that constitutively express IL-2.
[0061] Embodiment 2. The method according to embodiment 1, wherein the IL-2 sensitized NK cells are NK cells previously and constitutively exposed to IL-2, preferably at least 100 IU / mL IL-2.
[0062] Embodiment 3. The method according to embodiment 1 or 2, wherein any one or more of the following is true:
[0063] The genetically modified NK cells are aNK cells, autologous NK cells, or NK cells derived in vitro from precursor cells;
[0064] The genetically modified NK cells constitutively express and retain IL-2 intracellularly;
[0065] The genetically modified NK cells are haNK cells or NK92MI cells; and
[0066] The IL-12 portion of the chimeric protein comprises an IL-12 α chain and an IL-12 β chain.
[0067] Embodiment 4. A method according to any one of the preceding embodiments, wherein the cancer cell targeting portion targets a necrosis marker or a cancer-associated antigen or a cancer neo-epitope, and wherein the necrosis marker is preferably DNA, RNA, or histone, and wherein the cancer cell targeting portion preferably comprises the hu51-4 antibody or a portion thereof.
[0068] Embodiment 5. The method according to any one of the preceding embodiments, wherein the chimeric protein comprises SEQ ID NO:1 or SEQ ID NO:2, and optionally SEQ ID NO:3.
[0069] Embodiment 6. The method according to any one of the preceding embodiments, wherein any one or more of the following are true:
[0070] The step of contacting the NK cell with the chimeric protein is performed ex vivo, and the NK cell is a haNK cell; and
[0071] The step of contacting the NK cell with the chimeric protein is performed in vivo, and the NK cell is a haNK cell or a NK92MI cell.
[0072] Example 7. A composition for treating cancer in a subject in need thereof, the composition comprising NK cells and a chimeric protein,
[0073] wherein the NK cell is an IL-2-sensitized NK cell or a genetically modified NK cell constitutively expressing IL-2; and
[0074] The chimeric protein comprises an IL-12 portion and a cancer cell targeting portion to induce the NK cells to secrete interferon gamma (IFNγ).
[0075] Embodiment 8. The composition according to embodiment 7, wherein the NK cell is a genetically modified NK cell that constitutively expresses and retains IL-2 intracellularly, and wherein the NK cell is preferably a haNK cell or a NK92MI cell.
[0076] Embodiment 9. The composition according to embodiment 7 or 8, wherein any one or more of the following are true:
[0077] The IL-12 portion of the chimeric protein comprises an IL-12 α chain and an IL-12 β chain;
[0078] The cancer cell targeting moiety comprises an IgG antibody portion, a Fab portion, a F(ab')2 portion, a Fab2 portion, or a scFv portion;
[0079] The cancer cell targeting moiety targets a necrosis marker or a cancer-associated antigen or a cancer neo-epitope;
[0080] The necrosis marker is DNA, RNA, or histone;
[0081] The cancer cell targeting moiety comprises the hu51-4 antibody or a portion thereof;
[0082] The chimeric protein comprises SEQ ID NO: 1 or SEQ ID NO: 2, and optionally SEQ ID NO: 3; and
[0083] The chimeric protein binds to the NK cell.
[0084] Embodiment 10. A chimeric protein comprising an IL-12 portion and a cancer cell targeting portion that targets a necrosis marker, and optionally wherein any one or more of the following are true:
[0085] The necrosis marker is DNA, RNA, or histone;
[0086] The cancer cell targeting moiety comprises the hu51-4 antibody or a portion thereof;
[0087] The IL-12 portion of the chimeric protein comprises an IL-12 α chain and an IL-12 β chain;
[0088] The chimeric protein comprises SEQ ID NO: 1, and optionally SEQ ID NO: 3;
[0089] The chimeric protein comprises SEQ ID NO: 2, and optionally SEQ ID NO: 3, and
[0090] The cancer cell targeting moiety comprises an IgG antibody moiety, a Fab moiety, a F(ab')2 moiety, a Fab2 moiety or a scFv moiety.
[0091] Embodiment 11. The chimeric protein of embodiment 10, wherein the IL-12 portion can be covalently coupled to the cancer cell targeting portion, and optionally wherein the IL-12 portion is covalently coupled to the cancer cell targeting portion via a peptide linker.
[0092] Embodiment 12. The chimeric protein of embodiment 10 or 11, wherein the chimeric protein binds to CD16 of NK cells.
[0093] Embodiment 13. A pharmaceutical composition comprising the chimeric protein according to any one of embodiments 10-12.
[0094] Embodiment 14. A pharmaceutical composition according to embodiment 13, wherein the composition further comprises NK cells, wherein the NK cells are IL-2 sensitized NK cells or genetically modified NK cells constitutively expressing IL-2, and optionally wherein any one or more of the following are correct:
[0095] The NK cells are haNK cells;
[0096] The NK cells are NK92MI cells; and
[0097] The chimeric protein binds to CD16 of NK cells.
[0098] Embodiment 15. A chimeric antibody comprising a chimeric heavy chain comprising a scIL-12 portion and an antigen binding portion that binds a cell death-exposing antigen, and optionally wherein any one or more of the following are true:
[0099] The scIL-12 comprises an IL-12α subunit connected to an IL-12β subunit via a peptide linker;
[0100] The antibody comprises SEQ ID NO: 1, and optionally SEQ ID NO: 3; and
[0101] • The antibody comprises SEQ ID NO:2, and optionally SEQ ID NO:3.
[0102] Examples
[0103] To investigate the effects of constitutive exposure of NK cells to IL-2, three NK92 derivatives, aNK cells, haNK cells (commercially available from Nantquist), and NK92MI cells (commercially available from ATCC), were exposed to IL-12. Figure 1 The left panel comparatively depicts data for aNK cells that have not been exposed to constitutive IL-2 and haNK cells that have been exposed to constitutive IL-2, while the right panel depicts a stably integrated NK92 derivative (not expressing high-affinity CD16 variants) including an IL-2 expression cassette. As can be seen from these results, the modified NK cells not only respond to IL-12 signaling to secrete IFNγ, but also secrete unexpectedly large amounts of IFNγ (peak value close to 200ng / mL).
[0104] More specifically, NK-92 cells were previously transfected with human IL-2 cDNA in a retroviral MFG-hIL-2 vector by particle-mediated gene transfer. The transfection was stable. NK-92 and the derivative cell line NK-92MI have the following characteristics: surface markers are bright positive for CD2, CD7, CD11a, CD28, CD45, CD54 and CD56; surface markers are negative for CD1, CD3, CD4, CD5, CD8, CD10, CD14, CD16, CD19, CD20, CD23, CD34 and HLA-DR. Cells were grown according to standard protocols. IFNγ was measured using conventional ELISA methods well known in the art.
[0105] In another set of experiments, haNK cells (i.e., aNK cell derivatives expressing high affinity CD16 and retaining IL-2 intracellularly) were cultured overnight in the presence of human recombinant IL-12 (rHuIL-12), and selected human or murine recombinant IL-12-Ab chimeric constructs (HuIL-12 / Hu51-4 and MuIL-12 / Hu51-4) having the sequences of SEQ ID NO: 1 and SEQ ID NO: 3 or SEQ ID NO: 2 and SEQ ID NO: 3. 5 Cells were cultured by seeding 10 cells per well in a 24-well plate in X-Vivo 10 containing 5% human serum. Cell culture supernatants were then collected and human IFN-γ was measured by ELISA. Notably, constitutive IL-2 exposure via intracellular IL-2 expression renders haNK cells sensitive to IL-12 signaling, as can be easily determined from Figure 2 Indeed, exposure to various forms of IL-12 resulted in significant IFNγ secretion of both murine and human IL-12. As expected, human IL-12 produced stronger IFNγ secretion in haNK cells than murine IL-12.
[0106] In another set of experiments, haNK cells (i.e., aNK cell derivatives expressing high affinity CD16 and retaining IL-2 intracellularly) were cultured overnight in the presence of human recombinant IL-12 (rHuIL-12), and selected human or murine recombinant IL-12-Ab chimeric constructs (HuIL-12 / Hu51-4 and MuIL-12 / Hu51-4) having the sequences of SEQ ID NO: 1 and SEQ ID NO: 2 or SEQ ID NO: 1 and SEQ ID NO: 3. 5 Cells were cultured by seeding 10 cells per well in a 24-well plate in X-Vivo 10 containing 5% human serum. Cell culture supernatants were then collected and human IFN-γ was measured by ELISA. Notably, constitutive IL-2 exposure via intracellular IL-2 expression renders haNK cells sensitive to IL-12 signaling, as can be easily determined from Figure 2 Indeed, exposure to various forms of IL-12 resulted in significant IFNγ secretion of both murine and human IL-12. As expected, human IL-12 produced stronger IFNγ secretion in haNK cells than murine IL-12.
[0107] The binding specificity of the chimeric proteins HuIL-12 / Hu51-4 and MuIL-12 / Hu51-4 to necrotic cells was evaluated using dying Raji cancer cells (human Burkitt's lymphoma cells), and exemplary results are described in Figure 3 As shown, the results of the negative control (NC), the positive control (PC), and the binding of HuIL-12 / Hu51-4 and MuIL-12 / Hu51-4 are shown. It can be easily seen from the chart that HuIL-12 / Hu51-4 and MuIL-12 / Hu51-4 avidly bind to the target antigen in dead cells. Exemplary sequences of HuIL-12 / Hu51-4 and MuIL-12 / Hu51-4 are also described in Figure 4 middle.
[0108] In some embodiments, the numbers representing the amount of components, characteristics (such as concentration), reaction conditions, etc., used to describe and claim certain embodiments of the present invention should be understood to be modified by the term "about" in some cases. Therefore, in some embodiments, the numerical parameters listed in the written specification and the appended claims are approximate values, which can vary according to the desired characteristics that a particular embodiment attempts to obtain. In some embodiments, the numerical parameters should be interpreted according to the number of reported significant figures and by applying ordinary rounding techniques. Although the numerical ranges and parameters of the wide range of some embodiments of the present invention are approximate values, the numerical values set forth in the specific examples are reported as accurately as practicable. The numerical values presented in some embodiments of the present invention may contain certain errors caused by the standard deviation found in their respective test measurements. Unless the context indicates otherwise, all ranges listed herein should be interpreted as including their endpoints, and open ranges should be interpreted as including commercially practical values. Similarly, unless the context indicates otherwise, the list of all values should be considered to include intermediate values.
[0109] As used in the specification herein and throughout the claims that follow, the meanings of "a", "an", and "the" include plural references unless the context clearly indicates otherwise. Also, as used in the specification herein, the meaning of "in" includes "in" and "on", unless the context clearly indicates otherwise. Also, and unless the context indicates otherwise, the term "coupled to" is intended to include direct coupling (where two elements coupled to each other are in contact with each other) and indirect coupling (where at least one additional element is located between the two elements). Thus, the terms "coupled to" and "coupled with" are used synonymously.
[0110] Furthermore, as used herein, the phrase "at least one of A and B" is intended to refer to 'A' and / or 'B', regardless of the nature of 'A' and 'B'. For example, in some embodiments, 'A' may be a single different species, while in other embodiments, 'A' may represent a single species within the genus referred to as 'A'. Likewise, in some embodiments, 'B' may be a single different species, while in other embodiments, 'B' may represent a single species within the genus referred to as 'B'.
[0111] It should be clear to those skilled in the art that, without departing from the inventive concept of this article, in addition to those already described, more modifications are possible. Therefore, the subject matter of the present invention is only limited to the scope of the appended claims. In addition, when interpreting the specification and claims, all terms should be interpreted in a manner as broad as possible consistent with the context. In particular, the term "comprises" and "comprising" should be interpreted as referring to elements, components or steps in a non-exclusive manner, thereby indicating that the mentioned elements, components or steps can exist, or use, or combine with other elements, components or steps not explicitly mentioned. In the case where the specification claims mention at least one of something selected from the group consisting of A, B, C ... and N, the text should be interpreted as requiring only one element in the group, rather than A plus N, or B plus N, etc.
Claims
1. Use of a chimeric protein in the preparation of a medicament or kit for treating cancer, wherein the chimeric protein comprises an IL-12 portion and a cancer cell targeting portion, wherein the chimeric protein comprises scIL-12 in a single polypeptide sequence, wherein the IL-12α subunit and the IL-12β subunit are coupled to each other via a peptide linker, and wherein scIL-12 is coupled to the N-terminus of the cancer cell targeting portion, and wherein the cancer cell targeting portion consists of an antibody heavy chain and a light chain, wherein the antibody heavy chain consists of the amino acid sequence of amino acids 539-991 of SEQ ID NO:2, and the light chain consists of the amino acid sequence of amino acids 24-236 of SEQ ID NO:
3.
2. The use according to claim 1, wherein the IL-12 moiety is covalently coupled to the cancer cell targeting moiety via a peptide linker.
3. The use according to claim 1, wherein the peptide linker is a flexible (G4S)3 linker.
4. The use according to claim 1, wherein the treatment comprises inducing IFNγ secretion by natural killer (NK) cells at the tumor site.
5. The use according to claim 1, wherein the MHC-I expression in the tumor is increased.
6. Use of a pharmaceutical composition in the preparation of a medicament or kit for treating cancer, the composition comprising a chimeric protein and NK cells, wherein the chimeric protein comprises an IL-12 portion and a cancer cell targeting portion, and wherein the chimeric protein comprises scIL-12 in a single polypeptide sequence, wherein the IL-12α subunit and the IL-12β subunit are coupled to each other via a peptide linker, and wherein scIL-12 is coupled to the N-terminus of the cancer cell targeting portion, and wherein the cancer cell targeting portion consists of an antibody heavy chain and a light chain, the antibody heavy chain consisting of the amino acid sequence of amino acids 539-991 of SEQ ID NO:2, and the light chain consisting of the amino acid sequence of amino acids 24-236 of SEQ ID NO:
3.
7. The use according to claim 6, wherein the NK cells are primary NK cells.
8. The use according to claim 6, wherein the NK cells are genetically modified NK cells that constitutively express and retain IL-2 intracellularly.
9. The use according to claim 6, wherein the NK cells are haNK cells, aNK cells or NK92MI cells.
10. The use according to claim 6, wherein the NK cell comprises a chimeric antigen receptor (CAR).
11. The use according to claim 10, wherein the CAR comprises a scFv portion having binding specificity for a tumor-associated antigen, a tumor-specific antigen or a new epitope.
12. The use according to claim 6, wherein the chimeric protein binds to NK cells.
13. Use of a composition according to claim 6, wherein the composition is administered to a patient.
14. The use according to claim 6, wherein the chimeric protein is administered at least 12 hours before the administration of the NK cells, or wherein the chimeric protein is administered at least 12 hours after the administration of the NK cells.
15. The use according to claim 6, wherein the chimeric protein and the NK cells are administered simultaneously.
16. The use according to claim 6, wherein the secretion of IFNγ caused by NK cells at the tumor site is increased.
17. The use according to claim 6, wherein MHC-I expression in the tumor is increased.
18. A kit comprising a chimeric protein, NK cells, and instructions for use thereof, wherein the chimeric protein comprises an IL-12 portion and a cancer cell targeting portion, and wherein the chimeric protein comprises scIL-12 in a single polypeptide sequence, wherein the IL-12α subunit and the IL-12β subunit are coupled to each other via a peptide linker, and wherein scIL-12 is coupled to the N-terminus of the cancer cell targeting portion, and wherein the cancer cell targeting portion consists of an antibody heavy chain and a light chain, wherein the antibody heavy chain consists of the amino acid sequence of amino acids 539-991 of SEQ ID NO:2, and the light chain consists of the amino acid sequence of amino acids 24-236 of SEQ ID NO:
3.
19. The kit of claim 18, wherein the NK cells are formulated into a sterile injectable composition.
20. The kit of claim 19, wherein the sterile injectable composition comprises 1 x 10 4 Up to 1x10 11 cells.
21. The kit according to claim 18, wherein the sterile injectable composition comprises 1×10 5 Up to 1x10 9 cells.
22. The kit of claim 18, wherein the NK cells are primary NK cells.
23. The kit of claim 18, wherein the NK cells are genetically modified NK cells that constitutively express and retain IL-2 intracellularly.
24. The kit according to claim 18, wherein the NK cells are haNK cells, aNK cells or NK92MI cells.
25. The kit of claim 18, wherein the NK cells comprise a chimeric antigen receptor (CAR).
26. The kit of claim 25, wherein the CAR comprises a scFv portion having binding specificity for a tumor-associated antigen, a tumor-specific antigen, or a new epitope.
27. The kit of claim 18, further comprising chemotherapy.
28. The kit of claim 18, further comprising an antibody.
29. The kit of claim 28, wherein the antibody is specific for tumor cells.
